• Cycloheximide: Benchmark Protein Biosynthesis Inhibitor A824

  2026-06-13

  Cycloheximide is a highly validated protein biosynthesis inhibitor used to dissect translation-dependent processes in eukaryotic cells. Its rapid, reversible action enables precise studies of apoptosis, protein turnover, and posttranslational modification pathways. APExBIO’s A8244 formulation offers high purity and robust documentation for reproducible research.

• Qinggan Lidan Capsule Mitigates APAP Liver Injury via HIF-1α

  2026-06-12

  This study demonstrates that Qinggan Lidan Capsule (QGLDC), a traditional Chinese medicine, can attenuate acetaminophen-induced liver injury by suppressing HIF-1α signaling and protecting mitochondrial integrity, thereby reducing hepatocyte apoptosis. The findings clarify QGLDC's mechanism of action and highlight its potential as a therapeutic option for drug-induced liver injury.

• ATRX-Deficient Gliomas: Enhanced Sensitivity to RTK/PDGFR In

  2026-06-12

  This study provides mechanistic evidence that ATRX-deficient high-grade glioma cells are particularly vulnerable to multi-targeted receptor tyrosine kinase and PDGFR inhibitors. These findings suggest stratifying glioma patients by ATRX status may reveal new therapeutic opportunities and improve interpretation of targeted therapy trials.

• AO/PI Staining Solution: Fluorescent DNA Dyes for Reliable C

  2026-06-11

  AO/PI Staining Solution redefines cell viability analysis with robust live/dead discrimination, outperforming traditional dyes in fluorescence-based workflows. Its dual fluorescent DNA dyes deliver precise, interference-resistant quantification, making it ideal for disease modeling—including diabetic nephropathy research.

• Self-Adaptive Nanocarriers and ROS-Responsive Chemotherapy i

  2026-06-11

  This study introduces a dual-sensitive nanocarrier (DATCPT) engineered to overcome multiple physiological barriers in orthotopic pancreatic cancer, enhancing chemotherapeutic efficacy through pH and reactive oxygen species (ROS) responsiveness. The approach highlights the importance of robust intracellular ROS measurement in evaluating advanced drug delivery systems for challenging tumor microenvironments.

• LY294002: Decoding PI3K Inhibition in Tumor–Immune Crosstalk

  2026-06-10

  Explore the multifaceted roles of LY294002 as a PI3K/Akt/mTOR pathway inhibitor and autophagy modulator. This article uniquely focuses on its application in dissecting tumor–immune cell interactions, particularly macrophage polarization, offering fresh insights beyond standard protocols.

• First-Line Topotecan Regimens in Small Cell Lung Cancer: Ins

  2026-06-10

  This article examines recent evidence on the use of topotecan as a first-line therapy for small cell lung cancer (SCLC), focusing on its efficacy, toxicity profile, and comparison with established platinum-etoposide regimens. Findings highlight the potential of topotecan-based combinations to expand therapeutic options, particularly in cases where cumulative toxicity or resistance limits existing protocols.

• Self-Amplifying RNA Vaccines Offer Enhanced Protection for I

  2026-06-09

  This study demonstrates that self-amplifying RNA (saRNA) vaccines provide superior immunogenicity and dose-sparing efficacy against influenza, particularly for strains where conventional mRNA vaccines underperform. The findings support the strategic use of RNA platform innovations for more robust and durable influenza vaccine responses.

• BCKDK-STUB1-BCAT1 Axis Drives Glioblastoma Progression via P

  2026-06-09

  This study reveals a novel regulatory mechanism in glioblastoma (GBM) progression involving the interplay between BCKDK-mediated phosphorylation and STUB1-dependent ubiquitination of BCAT1. The identification of STUB1 as an E3 ligase for BCAT1 and the functional consequences of their interaction provide new insights into metabolic control in cancer, with implications for targeted intervention strategies.

• Sunitinib: Multi-Targeted RTK Inhibitor for Tumor Research

  2026-06-08

  Sunitinib empowers cancer biology research with potent, multi-targeted RTK inhibition, enabling precise interrogation of tumor angiogenesis and cell survival pathways. Recent innovations—such as synergistic metabolic targeting—unlock new potential for overcoming resistance in renal cell carcinoma and beyond.

• 5-Methyl-CTP: Enhancing mRNA Synthesis for Drug Development

  2026-06-08

  5-Methyl-CTP empowers reliable synthesis of modified mRNA with superior stability and translation efficiency, accelerating both research and therapeutic applications. This guide translates the latest breakthroughs in OMV-mediated mRNA delivery and advanced protocol integration for robust, reproducible mRNA workflows.

• GSTA1 Drives Glutathione Depletion in α-Amanitin Hepatotoxic

  2026-06-07

  This study demonstrates that upregulated GSTA1, rather than protecting against α-amanitin-induced liver injury, instead aggravates hepatotoxicity by accelerating glutathione depletion and oxidative stress. These findings reposition GSTA1 as a potential therapeutic target and biomarker in acute toxic liver injury models.

• Sulfachloropyridazine and Cecal Microbiome in E. tenella Inf

  2026-06-06

  This study systematically evaluates the effects of sulfachlorpyridazine, ethanamizuril, and their combination on the cecal microbial community and metabolome in chickens infected with Eimeria tenella. By integrating 16S rRNA sequencing and metabolomics, it uncovers how these interventions modulate pathogen-induced dysbiosis and metabolic perturbations, offering new perspectives for monitoring drug efficacy and optimizing anticoccidial strategies.

• HyperScribe™ T7 High Yield RNA Synthesis Kit: Reliable RNA f

  2026-06-05

  This article addresses key laboratory challenges in RNA synthesis for cell assays, highlighting how the HyperScribe™ T7 High Yield RNA Synthesis Kit (SKU K1047) delivers robust, reproducible results across diverse applications. Drawing on data and real-world scenarios, we examine experimental design, protocol optimization, and vendor selection to support informed decisions for biomedical researchers.

• ABT-199 (Venetoclax): Precision Apoptosis in Hematologic Res

  2026-06-05

  ABT-199 (Venetoclax) offers unmatched selectivity for Bcl-2, enabling precise dissection of mitochondrial apoptosis in hematologic malignancies. Optimize apoptosis assays and overcome resistance mechanisms with evidence-backed workflows and troubleshooting insights.

15673 records 1/1045 page Next 12345 下5页 Last page